home / stock / labp / labp news

LABP News and Press, Landos Biopharma Inc. From 10/28/21

Stock Information
Company Name: Landos Biopharma Inc.
Stock Symbol: LABP
Market: NASDAQ
Website: landosbiopharma.com
Menu
LABP LABP Quote LABP Short LABP News LABP Articles LABP Message Board
Get LABP Alerts

News, Short Squeeze, Breakout and More Instantly...
LABP - Landos Biopharma gets dosing underway in early-stage LABP-104 lupus study

Landos Biopharma (NASDAQ:LABP) has dosed the first subject in a Phase 1 study of LABP-104, a potentially first-in-class oral, small-molecule LANCL2 agonist, for the treatment of systemic lupus erythematosus. Systemic lupus erythematosus (SLE) is the most common type of the autoimmune dis...
LABP - Landos Biopharma Announces First Subject Dosed in a Phase 1 Study of LABP-104 for Systemic Lupus Erythematosus

Topline results are expected in the first half of 2022 A whole blood LABP-104 precision medicine signature will be assessed during the trial BLACKSBURG, Va., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical co...

LABP - Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Systemic Lupus Erythematosus

Phase 1 trial initiation expected before yearend with topline results in 1H 2022 BLACKSBURG, Va., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE ® Advanced A.I. platform to disco...

LABP - Landos Biopharma Announces Publication in Scientific Reports of Novel Preclinical Findings Demonstrating Omilancor's Therapeutic Potential in Models of Psoriasis and Further Validating the LANCL2 Mechanism

BLACKSBURG, Va., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE ® Advanced A.I. platform to discover and develop novel therapeutics for patients with autoimmune diseases, today announced t...
LABP - Wall Street Breakfast: The Week Ahead (Podcast)

You can read full article here. For further details see: Wall Street Breakfast: The Week Ahead (Podcast)

LABP - Catalyst watch for next week: GM, Box and IBM events, Altria drama and auto prices watch

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

LABP - Landos Biopharma to Participate in Truist Securities CEO Fireside Chat Series (Virtual)

BLACKSBURG, Va., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE ® advanced A.I. platform to develop novel therapeutics for patients with autoimmune diseases, today announced that Josep Ba...
LABP - Landos Biopharma to Collaborate on a Phase 2 Study of Omilancor in Crohn's Disease with the Icahn School of Medicine at Mount Sinai

Second Phase 2 trial of omilancor in Crohn’s disease (CD), expected to initiate in 2021 Awarded a $3 million NIH R01 grant from the U.S. National Institute of Diabetes and Digestive and Kidney Diseases to fund this study BLACKSBURG, Va., Sept. 20, 2021 (GLOBE NEWSWI...

LABP - Landos Biopharma to Present Results of LABP-104 in Lupus at the American College of Rheumatology Convergence 2021

Oral treatment with LABP-104 in preclinical models of Systemic Lupus Erythematosus (SLE) resulted in enhanced Treg function, decreased kidney inflammation and reduced interferon gamma signaling Phase 1 clinical trial anticipated to begin during Q4 2021 BLACKSBURG, Va., Sep...

LABP - Landos Biopharma to Participate in Two Upcoming Investor Conferences in September

BLACKSBURG, Va., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE ® Advanced A.I. platform to develop novel oral therapeutics for patients with autoimmune diseases, today announced that Jos...
Previous 10 Next 10